A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 25 Feb 2022
At a glance
- Drugs GPC3-CAR-T (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors CARsgen
Most Recent Events
- 08 Feb 2022 Status changed from recruiting to completed.
- 07 Oct 2020 Planned primary completion date changed from 22 Jun 2020 to 22 Aug 2021.
- 11 Oct 2019 Status changed from not yet recruiting to recruiting.